Cargando…

Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

With the rapid growth of advanced nanoengineering strategies, there are great implications for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial to direct immunostimulators to the right tissue and specific immune cells at the right time, thereby orchestrating...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Meihua, Yang, Wei, Yue, Wenwen, Chen, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762307/
https://www.ncbi.nlm.nih.gov/pubmed/36257824
http://dx.doi.org/10.1002/advs.202204335
_version_ 1784852837496258560
author Yu, Meihua
Yang, Wei
Yue, Wenwen
Chen, Yu
author_facet Yu, Meihua
Yang, Wei
Yue, Wenwen
Chen, Yu
author_sort Yu, Meihua
collection PubMed
description With the rapid growth of advanced nanoengineering strategies, there are great implications for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial to direct immunostimulators to the right tissue and specific immune cells at the right time, thereby orchestrating the desired, potent, and durable immune response against cancer. The flexibility of nanoformulations in size, topology, softness, and multifunctionality allows precise regulation of nano‐immunological activities for enhanced therapeutic effect. To grasp the modulation of immune response, research efforts are needed to understand the interactions of immune cells at lymph organs and tumor tissues, where the nanoformulations guide the immunostimulators to function on tissue specific subsets of immune cells. In this review, recent advanced nanoformulations targeting specific subset of immune cells, such as dendritic cells (DCs), T cells, monocytes, macrophages, and natural killer (NK) cells are summarized and discussed, and clinical development of nano‐paradigms for targeted cancer immunotherapy is highlighted. Here the focus is on the targeting nanoformulations that can passively or actively target certain immune cells by overcoming the physiobiological barriers, instead of directly injecting into tissues. The opportunities and remaining obstacles for the clinical translation of immune cell targeting nanoformulations in cancer therapy are also discussed.
format Online
Article
Text
id pubmed-9762307
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97623072022-12-20 Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation Yu, Meihua Yang, Wei Yue, Wenwen Chen, Yu Adv Sci (Weinh) Reviews With the rapid growth of advanced nanoengineering strategies, there are great implications for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial to direct immunostimulators to the right tissue and specific immune cells at the right time, thereby orchestrating the desired, potent, and durable immune response against cancer. The flexibility of nanoformulations in size, topology, softness, and multifunctionality allows precise regulation of nano‐immunological activities for enhanced therapeutic effect. To grasp the modulation of immune response, research efforts are needed to understand the interactions of immune cells at lymph organs and tumor tissues, where the nanoformulations guide the immunostimulators to function on tissue specific subsets of immune cells. In this review, recent advanced nanoformulations targeting specific subset of immune cells, such as dendritic cells (DCs), T cells, monocytes, macrophages, and natural killer (NK) cells are summarized and discussed, and clinical development of nano‐paradigms for targeted cancer immunotherapy is highlighted. Here the focus is on the targeting nanoformulations that can passively or actively target certain immune cells by overcoming the physiobiological barriers, instead of directly injecting into tissues. The opportunities and remaining obstacles for the clinical translation of immune cell targeting nanoformulations in cancer therapy are also discussed. John Wiley and Sons Inc. 2022-10-18 /pmc/articles/PMC9762307/ /pubmed/36257824 http://dx.doi.org/10.1002/advs.202204335 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Yu, Meihua
Yang, Wei
Yue, Wenwen
Chen, Yu
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
title Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
title_full Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
title_fullStr Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
title_full_unstemmed Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
title_short Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
title_sort targeted cancer immunotherapy: nanoformulation engineering and clinical translation
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762307/
https://www.ncbi.nlm.nih.gov/pubmed/36257824
http://dx.doi.org/10.1002/advs.202204335
work_keys_str_mv AT yumeihua targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation
AT yangwei targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation
AT yuewenwen targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation
AT chenyu targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation